The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
1
|
L | Antineoplastic and immunomodulating agents | |
2
|
L02 | Endocrine therapy | |
3
|
L02B | Hormone antagonists and related agents | |
4
|
L02BA | Anti-estrogens | |
5
|
L02BA05 |
| Active Ingredient |
|---|
|
Camizestrant is an oral selective oestrogen receptor degrader (SERD) and oestrogen receptor (ER) antagonist. Camizestrant binds to the ligand binding domain of ERα, antagonising the activity of ERα encoded by both wild-type ESR1 and mutated ESR1, and inducing proteasome-dependent degradation of ERα, without agonising ERα. |